Global Dental Burs Market 2024
The global dental burs market is projected to expand at a CAGR of ~5.6 percent across the forecast period of 2024 – 2030, according to the latest edition of the…
$1,350.00
According to market research study published by Gen Consulting Company, the global natural killer cell therapy market is predicted to be growing at a CAGR of over 36.8% from 2022 to 2028.
This industry report offers market estimates of the global market, followed by a detailed analysis of the therapy type, indication, and region. The global market data on natural killer cell therapy can be segmented by therapy type: CAR-NK cell therapy (modified), NK cell engager, NK cell therapy (unmodified). Natural killer cell therapy market is further segmented by indication: acute myeloid leukemia (AML), hepatocellular carcinoma (HCC), peripheral T-cell lymphoma (PTCL), relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). Based on region, the natural killer cell therapy market is segmented into: Asia Pacific, Europe, North America.
The global natural killer cell therapy market is highly competitive. The leading players in the natural killer cell therapy market include Acepodia Inc., Affimed N.V., Celularity Inc., Century Therapeutics Inc., Cytovac A/S, Dragonfly Therapeutics Inc., Fate Therapeutics Inc., Gamida-Cell Ltd., GC Biopharma Corp., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio Inc., Innate Pharma S.A., Nkarta Inc., Sanofi S.A., Senti Biosciences Inc., Shoreline Biosciences Inc., Takeda Pharmaceutical Company Limited, VaxCell Biotherapeutics Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
– Get a detailed picture of the Global Natural Killer Cell Therapy Market
– Identify segments/areas to invest in over the forecast period in the Global Natural Killer Cell Therapy Market
– Understand the competitive environment, the market’s leading players
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.
Part 1. Summary
Part 2. Introduction
· Study period
· Geographical scope
· Market segmentation
Part 3. Natural killer cell therapy market overview
Part 4. Market breakdown by therapy type
· CAR-NK cell therapy (modified)
· NK cell engager
· NK cell therapy (unmodified)
Part 5. Market breakdown by indication
· Acute myeloid leukemia (AML)
· Hepatocellular carcinoma (HCC)
· Peripheral T-cell lymphoma (PTCL)
· Relapsed/refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL)
Part 6. Market breakdown by region
· Asia Pacific
· Europe
· North America
Part 7. Key companies
· Acepodia Inc.
· Affimed N.V.
· Celularity Inc.
· Century Therapeutics, Inc.
· Cytovac A/S
· Dragonfly Therapeutics, Inc.
· Fate Therapeutics, Inc.
· Gamida-Cell Ltd.
· GC Biopharma Corp.
· Glycostem Therapeutics B.V.
· iCell Gene Therapeutics, LLC
· ImmunityBio, Inc.
· Innate Pharma S.A.
· Nkarta, Inc.
· Sanofi S.A.
· Senti Biosciences, Inc.
· Shoreline Biosciences, Inc.
· Takeda Pharmaceutical Company Limited
· VaxCell Biotherapeutics Co., Ltd.
Part 8. Methodology
Acepodia Inc.
Affimed N.V.
Celularity Inc.
Century Therapeutics, Inc.
Cytovac A/S
Dragonfly Therapeutics, Inc.
Fate Therapeutics, Inc.
Gamida-Cell Ltd.
GC Biopharma Corp.
Glycostem Therapeutics B.V.
iCell Gene Therapeutics, LLC
ImmunityBio, Inc.
Innate Pharma S.A.
Nkarta, Inc.
Sanofi S.A.
Senti Biosciences, Inc.
Shoreline Biosciences, Inc.
Takeda Pharmaceutical Company Limited
VaxCell Biotherapeutics Co., Ltd.
REPORT ATTRIBUTE | DETAILS |
---|---|
Base Year | 2021 |
Forecast Year | 2022-2028 |
CAGR (2022-2028) | 36.8% |
Pages | 24 |
Key Players | Acepodia Inc., Affimed N.V., Celularity Inc., Century Therapeutics Inc., Cytovac A/S, Dragonfly Therapeutics Inc., Fate Therapeutics Inc., Gamida-Cell Ltd., GC Biopharma Corp., Glycostem Therapeutics B.V., iCell Gene Therapeutics LLC, ImmunityBio Inc., Innate Pharma S.A., Nkarta Inc., Sanofi S.A., Senti Biosciences Inc., Shoreline Biosciences Inc., Takeda Pharmaceutical Company Limited, VaxCell Biotherapeutics Co. Ltd. |
The global dental burs market is projected to expand at a CAGR of ~5.6 percent across the forecast period of 2024 – 2030, according to the latest edition of the…
The global urology laser market is estimated to increase at the rate of 5.6% each year in the period from 2023 to 2029. Urology lasers are medical devices specifically designed…
The global scar management market, in terms of revenue, is anticipated to progress at a CAGR of 5.8% during the forecast period, 2023-2029. Scar management encompasses various techniques and treatments…
Please fill out our form and we will get back to you.